Weighted Average Number of Shares Outstanding, Diluted of ADIAL PHARMACEUTICALS, INC. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
ADIAL PHARMACEUTICALS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • ADIAL PHARMACEUTICALS, INC. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 668,630, a 245% increase year-over-year.
  • ADIAL PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 668,630, a 245% increase from 2024.
  • ADIAL PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 194,059, a 86% decline from 2023.
  • ADIAL PHARMACEUTICALS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 1,424,661, a 42% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

ADIAL PHARMACEUTICALS, INC. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 668,630 +474,571 +245% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 22,171,309 +16,335,627 +280% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 10,622,720 +6,439,960 +154% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 6,539,760 +3,585,847 +121% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 194,059 -1,230,602 -86% 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 5,835,682 +4,657,145 +395% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 4,182,760 +3,051,324 +270% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 2,953,913 -23,509,646 -89% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 1,424,661 +423,156 +42% 01 Oct 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 1,178,537 +149,555 +15% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 1,131,436 +158,795 +16% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 26,463,559 +3,312,366 +14% 01 Jan 2023 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 1,001,505 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 1,028,982 -18,819,126 -95% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 972,641 -16,616,199 -94% 01 Apr 2022 30 Jun 2022 10-Q/A 30 Oct 2023 2023 Q2
Q1 2022 23,151,193 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 19,848,108 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 17,588,840 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2019 482,555 +308,273 +177% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2019 2019 Q1
Q1 2018 174,282 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1

ADIAL PHARMACEUTICALS, INC. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 668,630 +474,571 +245% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 194,059 -1,230,602 -86% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 1,424,661 +423,156 +42% 01 Jan 2023 31 Dec 2023 10-K 04 Mar 2025 2024 FY
2022 1,001,505 -17,587,243 -95% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 18,588,748 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2018 243,182 +68,900 +40% 01 Jan 2018 31 Dec 2018 10-K 19 Feb 2019 2018 FY
2017 174,282 01 Jan 2017 31 Dec 2017 10-K 19 Feb 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.